| Document |
Document Title |
|
WO/2021/133430A1 |
Disclosed herein are compositions and methods for ovulation induction in females in need thereof. Current methods for inducing ovulation have unpleasant side effects and are expensive. The disclosed compositions and methods are safe, eff...
|
|
WO/2021/130779A1 |
The invention provides for a compound having the structure of Formula (I) to Formula (VI), including Compounds 1 to 6, their pharmaceutically acceptable salts, and compositions comprising thereof. This invention further includes methods ...
|
|
WO/2021/129915A1 |
Described is a GBD-SSTad-SSTad recombinant protein and a method for producing same on a glucan, which includes binding a GBD-SSTad-SSTad protein contained in cell extracts of E. coli strain BL21 [pGBD-SSTad-SSTad] with an alpha glycan-co...
|
|
WO/2021/133563A1 |
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in th...
|
|
WO/2021/129465A1 |
A novel crystal of Resmetirom (referred to as "compound I"), a preparation method therefor, a pharmaceutical composition comprising the crystal, and uses of the crystal in preparing a THR-β selective agonist medicament and a medicament ...
|
|
WO/2021/129362A1 |
The present invention provides a use of an AMHR2 recombinant protein or fusion protein in preparation of drugs for treating AMH signal axis abnormal activation related diseases, in particular, a use in preparation of AMH neutralizers or ...
|
|
WO/2021/129827A1 |
Disclosed are a compound as shown in formula (IV), an isomer thereof and a pharmaceutically acceptable salt thereof. The compound can be used for preparing medicaments in the treatment of diseases related to a THR-β agonist.
|
|
WO/2021/127376A1 |
Methods for treating and differential diagnosis between ACTH-Dependent and ACTH-Independent Cushing's syndrome are disclosed, in which a glucocorticoid receptor antagonist (GRA) is administered to a Cushing's syndrome patient with a basa...
|
|
WO/2021/126990A1 |
The present invention provides novel oxytocin derivative compounds that contain a fatty acid moiety that is conjugated to a modified oxytocin scaffold. The oxytocin derivative compounds of the invention are potent oxytocin agonists with ...
|
|
WO/2021/126693A1 |
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in th...
|
|
WO/2021/127273A1 |
Described herein are compounds of formulae (I), (lla) and (Mb) as prolyl hydroxylase inhibitors, HIF-lalpha stabilizers and PGK up regulators for use in treating inflammatory diseases, cancer or infections: Preferred compounds are e.g. t...
|
|
WO/2021/116874A1 |
The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dio
xol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-
1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan...
|
|
WO/2021/115272A1 |
Provided are a calcium-sensing receptor (CaSR) agonist compound and application thereof. Specifically, provided are a series of polypeptide CaSR agonist compounds and pharmaceutically acceptable salts thereof, which have agonist effects ...
|
|
WO/2021/113263A1 |
Compounds are provided herein that antagonize corticotropin-releasing factor (CRF) receptors, in particular CRF receptor 1 (CRF1), as well as related preparations, compositions and methods for treating diseases and/or disorders that woul...
|
|
WO/2021/110887A1 |
The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. Th...
|
|
WO/2021/110883A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
|
|
WO/2021/111179A1 |
The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-
1-(3-fluoro-4- methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-...
|
|
WO/2021/110884A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
|
|
WO/2020/189886A9 |
The present invention relates to biodegradable polymer microparticles containing a steroid-based drug and a preparation method therefor. Biodegradable polymer microparticles containing a steroid-based drug are prepared by a preparation m...
|
|
WO/2021/110886A1 |
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid ...
|
|
WO/2021/104288A1 |
The present invention provides a 1,2,4-triazine-3,5-dione compound, a preparation method therefor, and an application thereof. The 1,2,4-triazine-3,5-dione compound having a structure represented by formula (I) provided by present invent...
|
|
WO/2021/105075A1 |
The present invention relates to a compound having general formula I for use in the activation of AMPK. A composition comprising said compound for use in the activation of AMPK is also provided.
|
|
WO/2021/107646A1 |
The present invention provides a method for efficiently and economically producing Maxacalcitol, and an intermediate used therefor.
|
|
WO/2021/105076A1 |
The present invention relates to a compound having general formula I for use in the activation of AMPK. A composition comprising said compound for use in the activation of AMPK is also provided.
|
|
WO/2021/106975A1 |
The present invention provides a heterocyclic compound having orexin receptor type 2 agonist activity. A compound represented by formula (I) (in the formula, each symbol is as described in the specification) or a salt thereof has orexi...
|
|
WO/2021/107414A1 |
The present invention relates to a composition for preventing, alleviating or treating androgen-dependent diseases, containing a bamboo leaf extract as an active ingredient. Compared to other types of bamboo extracts, a bamboo leaf extra...
|
|
WO/2021/107023A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, and specifically, an orexin type-2 receptor, said agent containing a novel compound having a urea skeleton or a ph...
|
|
WO/2021/098810A1 |
A compound used as a non-steroidal selective androgen receptor modulator, and an application thereof in preparing a drug for treating related diseases mediated by androgen receptors. The compound as shown in formula (I), or a pharmaceuti...
|
|
WO/2021/098809A1 |
Disclosed are a bicyclic compound used as a non-steroidal selective androgen receptor modulator and the use thereof in the preparation of a drug for treating related diseases which are mediated by an androgen receptor. Specifically, the ...
|
|
WO/2021/100059A1 |
The application relates to a process for manufacturing substituted chroman compounds in an economically scalable manner, without the use of pyrophoric reagents. Also described are synthesis routes that do not include column chromatograph...
|
|
WO/2021/097437A1 |
Interfering nucleic acids and methods of their use in treat prostate cancers, such as aggressive prostate cancers. The nucleic acids may be, for example, short interfering RNA (siRNA), short hairpin RNA (shRNA), antisense RNA, antisense ...
|
|
WO/2021/094209A1 |
The invention relates to substituted pyrrole triazine carboxamide derivatives of formula (I) and to processes for their preparation, and also /to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in p...
|
|
WO/2021/094210A1 |
The invention relates to substituted pyrazine carboxamide derivatives of formula (I) and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in particular...
|
|
WO/2021/093820A1 |
An amide derivative and an application thereof in medicine, specifically relating to the amide derivative represented by general formula (I) or a stereoisomer, solvate, a metabolic product, a deuterated product, a prodrug, a pharmaceutic...
|
|
WO/2021/089554A1 |
The present disclosure relates to the use of a novel dosage form of merotocin in improving lactation in a female in need thereof. The disclosure particularly provides the use of a composition suitable for intranasal administration that p...
|
|
WO/2021/092358A1 |
The present inventive concept is related to a modified follicle-stimulating hormone (FSH), in particular, a hypo-glycosylated form of FSH, as well as compositions and formulations including, nucleic acids encoding, cell lines expressing,...
|
|
WO/2021/091788A1 |
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in th...
|
|
WO/2021/085518A1 |
The present invention discloses an aqueous pharmaceutical composition containing a protein in which serum albumin and growth hormone are linked. The aqueous pharmaceutical composition contains, as an active ingredient, a fusion protein o...
|
|
WO/2021/087035A1 |
An ankle-brace that incorporates an anti-rotation feature. The brace includes a conventional unified foot and ankle enclosure. One or more lateral straps are provided. Each of these straps is configured to be wrapped around the anterior ...
|
|
WO/2021/078274A1 |
The present invention relates to a pyridazinone or pyridazine compound and a derivative and a pharmaceutical composition thereof. Specifically, the present invention provides a pyridazinone or pyridazine compound as shown in formula (I) ...
|
|
WO/2021/075491A1 |
A transdermal absorption-type patch (10) comprises a support body (1) and an adhesive layer (2) layered on the support body (1). The adhesive layer (2) contains: a solid composite body (2a) in which an active ingredient having a molecula...
|
|
WO/2021/073742A1 |
The present disclosure relates to agonists of Tacr2, such as peptides agonist of Tacr2 and methods of using the same for treatment of insulin resistance, obesity and/or diabetes. The disclosure also relates to use of said agonists of Tac...
|
|
WO/2021/071451A1 |
The invention, in order to be used in the healthcare industry provided by biotechnology-nanotechnology, a targeted dual cytotoxic effective nano-metallo system for the treatment of non-metastasized castration-resistant prostate cancer, c...
|
|
WO/2021/068239A1 |
Disclosed are a vaginal slow-release administration system for luteal support, a preparation method therefor and a use thereof. The system is a progesterone reservoir type vaginal ring, comprising a core layer, and a film layer double-la...
|
|
WO/2021/069740A1 |
The invention relates to the field of radiation oncology. The method according to the invention comprises the use of botulinum toxin and an anticholinergic agent to prevent glands from radiation damage and side-effects due to radioligand...
|
|
WO/2021/064421A1 |
The present invention relates to treatment of AR-related disorders by modulating the levels of AR2, which is a naturally occurring AR variant and is capable of modulating AR transcriptional activity.
|
|
WO/2021/063967A1 |
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...
|
|
WO/2021/062347A1 |
The present invention provides compositions and methods for preventing or treating pancreatitis by administering a composition comprising an effective amount of phosphate to the subject so as to treat or prevent pancreatitis in the subje...
|
|
WO/2021/062246A1 |
Compounds are provided herein, as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).
|
|
WO/2021/057791A1 |
Provided are a chemical compound as a thyroid hormone Beta receptor agonist and a use thereof, further comprising a pharmaceutical composition containing the chemical compound. The chemical compound or pharmaceutical composition can be u...
|
